Detalles de la búsqueda
1.
Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma.
N Engl J Med
; 383(13): 1218-1230, 2020 09 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-32945632
2.
Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.
N Engl J Med
; 380(12): 1103-1115, 2019 03 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-30779531
3.
Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial.
Lancet Oncol
; 19(4): 451-460, 2018 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-29530667
4.
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.
Lancet Oncol
; 16(1): 25-35, 2015 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-25524798
5.
Avelumab in relapsed/refractory classical Hodgkin lymphoma: phase 1b results from the JAVELIN Hodgkins trial.
Blood Adv
; 5(17): 3387-3396, 2021 09 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-34477818
6.
PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro.
Breast Cancer Res
; 11(5): R77, 2009.
Artículo
en Inglés
| MEDLINE | ID: mdl-19874578
7.
Brostallicin, an agent with potential activity in metastatic soft tissue sarcoma: a phase II study from the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
Eur J Cancer
; 43(2): 308-15, 2007 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-17095209
8.
A phase I dose-escalation and pharmacokinetic study of brostallicin (PNU-166196A), a novel DNA minor groove binder, in adult patients with advanced solid tumors.
Clin Cancer Res
; 10(2): 468-75, 2004 Jan 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-14760067
9.
Phase I and pharmacokinetic study of brostallicin (PNU-166196), a new DNA minor-groove binder, administered intravenously every 3 weeks to adult patients with metastatic cancer.
Clin Cancer Res
; 9(8): 2957-64, 2003 Aug 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-12912942
10.
Towards new methods for the determination of dose limiting toxicities and the assessment of the recommended dose for further studies of molecularly targeted agents--dose-Limiting Toxicity and Toxicity Assessment Recommendation Group for Early Trials of Targeted therapies, an European Organisation for Research and Treatment of Cancer-led study.
Eur J Cancer
; 50(12): 2040-9, 2014 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-24880774
11.
Phase I, open-label, multicentre, dose-escalation, pharmacokinetic and pharmacodynamic trial of the oral aurora kinase inhibitor PF-03814735 in advanced solid tumours.
Eur J Cancer
; 47(15): 2256-64, 2011 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-21852114
12.
Randomized phase III trial of paclitaxel/carboplatin with or without PF-3512676 (Toll-like receptor 9 agonist) as first-line treatment for advanced non-small-cell lung cancer.
J Clin Oncol
; 29(19): 2667-74, 2011 Jul 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-21632509
13.
Brostallicin: a new concept in minor groove DNA binder development.
Anticancer Drugs
; 15(1): 1-6, 2004 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-15090736
Resultados
1 -
13
de 13
1
Próxima >
>>